HERCULES, CA--(Marketwired - Jun 12, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced it ...

HERCULES, CA--(Marketwired - Jun 17, 2014) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global manufacturer and distributor of life science research and clinical diagnostic products, ...

Bio-Rad Laboratories, Inc. has announced the European and Canadian launch of its BioPlex® 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits for use on its BioPlex® 2200 system. Antiphospholipid ...

The US Food and Drug Administration (FDA) has approved the first-ever diagnostic test that differentiates between types of HIV infection. The Bio-Rad BioPlex 2200 HIV Ag-Ab assay (Bio-Rad Laboratories ...

Anti-CCP assay is based on the Bio-Rad BioPlex 2200 system. Axis-Shield and Bio-Rad Laboratories received FDA clearance of the BioPlex® 2200 Anti-CCP test for the detection of rheumatoid arthritis (RA ...

Anti-CCP assay will be run on the BioPlex 2200 system. Bio-Rad gained access to Axis-Shield’s test for the early detection of rheumatoid arthritis. The assay will run on Bio-Rad’s BioPlex® 2200 system ...

* Bio Rad Laboratories Inc - ‍has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay Source text for Eikon: Further company coverage: ...

Bio-Rad Laboratories, Inc. BIO recently announced the receipt of FDA approval for its advanced multiplex test method BioPlex 2200 Lyme Total Assay for the diagnosis of Lyme disease. Broadening the ...

Bio-Rad Laboratories, Inc. ( BIO) reported the launch of the BioPlex 2200 25-OH Vitamin D kit, which will be used in the company's BioPlex 2200 system. For now, the company has launched the kit only ...

Bio-Rad's BioPlex 2200 HIV Ag-Ab assay--Courtesy of Bio-Rad Laboratories Bio-Rad Laboratories ($BIO) snagged FDA approval for its next-generation HIV Ag-Ab test for ...